Pregnancy and Antiphospholipid Syndrome

Abstract

Antiphospholipid syndrome (APS) is classified as the association of thrombotic events and/or obstetric morbidity in patients persistently positive for antiphospholipid antibodies (aPL). APS is also the most frequently acquired risk factor for a treatable cause of recurrent pregnancy loss and increases the risk of conditions associated with ischemic placental dysfunction, such as stillbirth, intrauterine death, preeclampsia, premature birth, and fetal growth restriction. The use of low-dose aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS will deliver a viable live infant. However, current management does not prevent all maternal, fetal, and neonatal complications of APS and the current treatment fails in 20 to 30% of APS pregnancies, raising the need to explore other treatments to improve obstetrical outcome. Two clinical studies of retrospective design have suggested that the immunomodulator hydroxychloroquine (HCQ) may play a role in the prevention of pregnancy complications in women with aPL and APS. The randomized controlled multicenter trial of hydroxychloroquine versus placebo during pregnancy in women with antiphospholipid antibodies (HYPATIA) of HCQ versus placebo will provide scientific evidence on the use of HCQ in pregnant women with aPL.

Keywords

antiphospholipid antibodies - antiphospholipid syndrome - thrombophilia - pregnancy

• References

• 1 Wilson WA, Gharavi AE, Koike T , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (7) 1309-1311
• 2 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
• 3 Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26 (5) 324-326
• 4 Cervera R, Piette JC, Font J , et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (4) 1019-1027
• 5 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346 (10) 752-763
• 6 Rai RS, Regan L, Clifford K , et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (8) 2001-2005
• 7 Cervera R, Serrano R, Pons-Estel GJ , et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (6) 1011-1018
• 8 Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015; 11 (10) 586-596
• 9 Erkan D, Aguiar CL, Andrade D , et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13 (6) 685-696
• 10 Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016; 214 (2) 273.e1-273.e8
• 11 Mekinian A, Lazzaroni MG, Kuzenko A , et al; SNFMI and the European Forum on Antiphospholipid Antibodies. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015; 14 (6) 498-502
• 12 Schreiber KSS, Breen K, Jacobsen S , et al. HYPATIA - A prospective randomised controlled trial of HYdroxychloroquine versus placebo during Pregnancy in women with AnTIphospholipid Antibodies. ISTH 2015;
• 13 Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu'u-Lino TJ. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth 2016; 16: 117
• 14 Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20 (3) 231-236
• 15 Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M. Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol Arch Med Wewn 2012; 122 (10) 480-486
• 16 Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52 (9) 2774-2782
• 17 Out HJ, Bruinse HW, Christiaens GC , et al. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis 1991; 50 (8) 553-557
• 18 de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3 (9) 1993-1997
• 19 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
• 20 Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2011; 70 (8) 1517-1518
• 21 Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33 (11) 2214-2221
• 22 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
• 23 Lockshin MD, Kim M, Laskin CA , et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64 (7) 2311-2318
• 24 Tincani A, Balestrieri G, Allegri F , et al. Overview on anticardiolipin ELISA standardization. J Autoimmun 2000; 15 (2) 195-197
• 25 Pengo V, Ruffatti A, Legnani C , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
• 26 Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011; 128 (1) 77-85
• 27 Silver RM, Parker CB, Reddy UM , et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013; 122 (3) 641-657
• 28 Simchen MJ, Dulitzki M, Rofe G , et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90 (12) 1428-1433
• 29 Mekinian A, Loire-Berson P, Nicaise-Roland P , et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 2012; 94 (2) 222-226
• 30 Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179 (2) 457-462
• 31 Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101 (5) 472-481
• 32 Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94 (7) 1746-1751
• 33 Jankowski M, Vreys I, Wittevrongel C , et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101 (1) 157-162
• 34 Ramesh S, Morrell CN, Tarango C , et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121 (1) 120-131
• 35 Pierangeli SS, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13 (5) 366-375
• 36 de Groot PG, Derksen RH. Pathophysiology of antiphospholipid antibodies. Neth J Med 2004; 62 (8) 267-272
• 37 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (6) 330-339
• 38 Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177 (4) 918-923
• 39 Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41 (3) 179-186
• 40 De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142 (7) 829-834
• 41 Stone S, Pijnenborg R, Vercruysse L , et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27 (4–5) 457-467
• 42 Derksen RH, de Groot PG. The obstetric antiphospholipid syndrome. J Reprod Immunol 2008; 77 (1) 41-50
• 43 Di Simone N, Meroni PL, de Papa N , et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43 (1) 140-150
• 44 Girardi G, Berman J, Redecha P , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
• 45 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
• 46 Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196 (2) 167.e1-167.e5
• 47 Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376 (9751) 1498-1509
• 48 Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180-185
• 49 Cervera R, Rodríguez-Pintó I, Colafrancesco S , et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014; 13 (7) 699-707
• 50 Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299 (6698) 541-545
• 51 RCOG. The Investigation and Treatment of Couples with Recurrent First- trimester and Second-trimester Miscarriage. Green–top Guideline No 17 2011
• 52 do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010; 116 (6) 1433-1443
• 53 Clark EAS, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?. Curr Rheumatol Rep 2007; 9 (3) 219-225
• 54 Yamada H, Atsumi T, Kobashi G , et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79 (2) 188-195
• 55 van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JI ; FRUIT Investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016; 197: 168-173
• 56 Rodger MA, Langlois NJ, de Vries JI , et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Rev 2014; 3: 69
• 57 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M ; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (1) 47-58
• 58 Cohen H, Hunt BJ, Efthymiou M , et al; RAPS trial Investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (9) e426-e436
• 59 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314 (7076) 253-257
• 60 Laskin CA, Spitzer KA, Clark CA , et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36 (2) 279-287
• 61 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174 (5) 1584-1589
• 62 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100 (3) 408-413
• 63 Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospohlipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 2012; 26 (1) 65-76
• 64 Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G , et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123 (3) 404-413
• 65 Bramham K, Hunt BJ, Germain S , et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19 (1) 58-64
• 66 Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117 (25) 6948-6951
• 67 Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009; 104 (3) 223-225
• 68 Girardi G. Can statins prevent pregnancy complications?. J Reprod Immunol 2014; 101–102: 161-167
• 69 Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS ONE 2010; 5 (10) e13663
• 70 Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009; 113 (17) 4101-4109
• 71 clinicaltrials.gov. Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery. Available at https://clinicaltrialsgov/ct2/show/NCT02314286?term=rosuvastatin+pregnancy&rank=1 2016
• 72 Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61 (1) 29-36
• 73 Mekinian A, Costedoat-Chalumeau N, Masseau A , et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. Autoimmun Rev 2015; 14 (1) 23-29
• 74 Hunt BJ. A novel antiphospholipid antibody agent?. Blood 2010; 115 (11) 2124-2125
• 75 The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324 (3) 150-154
• 76 Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheum 1987; 30 (12) 1435-1436
• 77 Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992; 51 (12) 1318-1321
• 78 Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 81 (5) 835-848
• 79 Flint J, Panchal S, Hurrell A , et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford); 2016
• 80 Flint J, Panchal S, Hurrell A , et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford); 2016
• 81 Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87 (3) 518-522
• 82 Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96 (12) 4380-4384
• 83 Rand JH, Wu XX, Quinn AS , et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115 (11) 2292-2299
• 84 Bertolaccini ML, Contento G, Lennen R , et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun 2016;
• 85 Chighizola CB, Gerosa M, Trespidi L , et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev Clin Immunol 2014; 10 (11) 1505-1517
• 86 Cantwell R, Clutton-Brock T, Cooper G , et al. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl. 01) 1-203
• 87 Gynaecologists RCoO. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No 37a 2015
• 88 Espinoza J, Kusanovic JP, Bahado-Singh R , et al. Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension?. J Ultrasound Med 2010; 29 (7) 1103-1115
• 89 Hunt BJ, Missfelder-Lobos H, Parra-Cordero M , et al. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J Thromb Haemost 2009; 7 (6) 955-961